openPR Logo
Press release

Hospital Acquired Pneumonia (HAP) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

04-04-2019 01:50 PM CET | Health & Medicine

Press release from: Pharma Proff

Hospital Acquired Pneumonia (HAP) Therapeutics- Pipeline

Hospital acquired pneumonia (HAP) is a lung infection that occurs during hospital stay. HAP can spread via health care workers, who may pass germs from their hands or clothes from one patient to another.

Download the sample report @

This is why hand-washing, wearing gowns, and using other safety measures is so important in hospitals and other healthcare settings. It has been observed that HAP may develop at least 48 hours after hospital admission.

Get the detailed analysis @

There are several risk factors associated with HAP including alcohol consumption, major surgery, weak immune system, chronic lung disease, and swallowing problems.

Make enquiry before purchase @

The disease can be treated with antibiotics and can be controlled by taking hygiene prevention during a hospital stay. Arsanis Inc. is in the process of developing ASN100 as a monoclonal antibody for the treatment of HAP. Some of the companies involved in HAP pipeline are Allecra Therapeutics GmbH and Nabriva Therapeutics plc among others.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hospital Acquired Pneumonia (HAP) Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments here

News-ID: 1688252 • Views: 349

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases

More Releases for HAP

Hydroxyapatite Hap Market Trends 2021 | Segmentation, Outlook, Industry Report t …
The Hydroxyapatite Hap Market size is expected to grow at an annual average of 5% during 2021-2027. Hydroxyapatite (HA) is a major component of normal bone and teeth already used as a coating for orthopedic implants to anchor and promote bone growth. Growing demand for dental and orthopedic implants along with growing popularity of bioactive materials and strong investment in R&D activities to expand the application of hydroxyapatite are expected
Hydroxyapatite (HAp) Market Size, Share, Development by 2025
LP INFORMATION recently released a research report on the Hydroxyapatite (HAp) analysis, which studies the Electrical Cord Reels's industry coverage, current market competitive status, and market outlook and forecast by 2025. Global “Hydroxyapatite (HAp) 2020-2025” Research Report categorizes the global Hydroxyapatite (HAp) by key players, product type, applications and regions,etc. The report also covers the latest industry data, key players analysis, market share, growth rate, opportunities
Hydroxyapatite Hap Market, Industry Share, Trends, Growth, Future Prospects, For …
The Hydroxyapatite (HAp) market is expected to grow by 6.5% CAGR from 2019 to 2025, growing from $2.2 billion in 2019 to $3.1 billion in 2025. Hydroxyapatite (HAp) is a mineral present in the bones and hard tissues of humans and animals. The micro-sized hydroxyapatite (HAp) can be designed using nanotechnology applicable to orthopedic surgery and drug delivery systems. It is mainly used for various bone graft methods, and is also
Global Hospital-Acquired Pneumonia (HAP) Drugs Market 2019 - Teva Pharmaceutical …
HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms.
Hydroxyapatite Market (HAp) 2018 Global Industry Trends, Share, Size and 2023 Fo …
2018-2023 Hydroxyapatite Market (HAp) research report presents a comprehensive study of the Hydroxyapatite Market in Global Industry; the study scans the progression of the market trailed over the past few years and the forecasts of growth in the coming years, primarily in terms of sales. The research report highlights the reasons liable for the disparities in the market and investigates them methodically. The Hydroxyapatite Market (HAp) effect factors have also
Global Hospital-acquired Pneumonia (HAP) Drugs Market Outlook 2017-2021
The study of Hospital-acquired Pneumonia (HAP) Drugs Market in UK 2017-2021 industry is very important to enhance business productivity and for the study of market forecast. This New Report presented by Orbis Reseach contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Hospital-acquired Pneumonia (HAP) Drugs is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of